drugset
drugset / Trial / NCT05494307

The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia

NCT05494307 ↗

Phase 2 Unknown 228 enrolled Peking University People's Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

A randomized, open-label, multicenter study to compare the efficacy and safety of terbutaline plus danazol compared to danazol monotherapy for the second-line treatment of adults with corticosteroid-resistant or relapsed primary immune thrombocytopenia (ITP).

Timeline

Start
2022-09-01
Primary completion
2023-09-01
Completion
2024-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Danazol Other / unclassified 200 mg Oral
Subject Terbutaline Small molecule 2.5 mg Oral

Indications

autoimmune thrombocytopenia